2001
Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users
Celentano D, Galai N, Sethi A, Shah N, Strathdee S, Vlahov D, Gallant J. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001, 15: 1707-1715. PMID: 11546947, DOI: 10.1097/00002030-200109070-00015.Peer-Reviewed Original ResearchConceptsInjection drug usersActive antiretroviral therapyAntiretroviral therapyDrug usersCell countLow health care accessNon-HAART regimensAntiretroviral therapy useDual combination therapyProportional hazards regressionMain outcome measuresMore treatment optionsHealth care accessNon-drug usersHAART regimenLow CD4HAART useHIV careCohort studyStudy clinicTherapy useSelf-reported initiationHazards regressionMethadone treatmentTreatment eligibility
1997
Long-term Perspective on the Prevalent-Cohort Biases in Studies of Human Immunodeficiency Virus Progression
Alcabes P, Pezzotti P, Phillips A, Rezza G, Vlahov D. Long-term Perspective on the Prevalent-Cohort Biases in Studies of Human Immunodeficiency Virus Progression. American Journal Of Epidemiology 1997, 146: 543-551. PMID: 9326431, DOI: 10.1093/oxfordjournals.aje.a009312.Peer-Reviewed Original ResearchConceptsPSP cohortRelative riskSeroincident cohortHIV infectionPrevalent cohortAIDS riskAcquired immunodeficiency syndrome (AIDS) diagnosisHuman immunodeficiency virus (HIV) infectionDisease Control case definitionHuman immunodeficiency virus (HIV) progressionImmunodeficiency syndrome diagnosisImmunodeficiency virus infectionPrevalent HIV infectionProportional hazards regressionAmbulatory care clinicsRate of progressionStudies of cohortsItalian National RegistryAIDS-free subjectsObserved relative riskSeroconversion datesHIV seroconversionCare clinicsHazards regressionNational registry